{"transactions":[{"id":934430,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69064,"kind":"person","name":"Wilson David Ian","position":1,"cik":"0002028949","reported_name":"Wilson David Ian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-21T16:01:32.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":8537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."}],"balance_after":15412,"derivative":{"underlying":"Common Stock","underlying_shares":8537},"source":{"system":"sec-edgar","filing":"0001213900-26-006173","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028949/000121390026006173/ownership.xml","form_type":"4"}},{"id":934431,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69065,"kind":"person","name":"Davies Peter Miles Winston","position":1,"cik":"0002030200","reported_name":"Davies Peter Miles Winston","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-21T16:01:30.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":8537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."}],"balance_after":15320,"derivative":{"underlying":"Common Stock","underlying_shares":8537},"source":{"system":"sec-edgar","filing":"0001213900-26-006171","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030200/000121390026006171/ownership.xml","form_type":"4"}},{"id":934432,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69066,"kind":"person","name":"Fisher Alan","position":1,"cik":"0002028654","reported_name":"Fisher Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-21T16:01:29.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":17073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."}],"balance_after":30731,"derivative":{"underlying":"Common Stock","underlying_shares":17073},"source":{"system":"sec-edgar","filing":"0001213900-26-006172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028654/000121390026006172/ownership.xml","form_type":"4"}},{"id":934429,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69063,"kind":"person","name":"Ryan Jane","position":1,"cik":"0002028936","reported_name":"Ryan Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-21T16:01:27.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":8537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock.1."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."}],"balance_after":15550,"derivative":{"underlying":"Common Stock","underlying_shares":8537},"source":{"system":"sec-edgar","filing":"0001213900-26-006170","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028936/000121390026006170/ownership.xml","form_type":"4"}},{"id":1014161,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":23615,"kind":"organization","name":"Lynx1 Capital Management LP","position":1,"cik":"0001910456","reported_name":"Lynx1 Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17934,"kind":"person","name":"Nichols Weston","position":2,"cik":"0001746376","reported_name":"Nichols Weston","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.00001 par value per share","published_at":"2025-10-23T23:49:54.000Z","date":"2025-10-21","kind":"purchase","planned":false,"acquired":true,"shares":639110,"price":5.137,"value":3283108.07,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the \"Investment Manager\") serves as investment manager. Weston Nichols (\"Mr. Nichols\") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":875328,"source":{"system":"sec-edgar","filing":"0000902664-25-004536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000090266425004536/ownership.xml","form_type":"4"}},{"id":1051292,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right-to- Buy)","published_at":"2025-09-02T11:02:44.000Z","date":"2025-08-27","kind":"grant","planned":false,"acquired":true,"shares":34559,"price":8.27,"value":285802.93,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested."}],"balance_after":74088,"derivative":{"exercise_price":8.27,"expiration_date":"2035-08-27","underlying":"Common Stock","underlying_shares":34559},"source":{"system":"sec-edgar","filing":"0001213900-25-082904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025082904/ownership.xml","form_type":"4"}},{"id":1142286,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right-to-Buy)","published_at":"2025-05-19T20:40:14.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":5.16,"value":139320.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares."}],"balance_after":39529,"derivative":{"exercise_price":5.16,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001213900-25-045445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025045445/ownership.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1169041,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":75908,"kind":"person","name":"Papapetropoulos Spyros","position":1,"cik":"0001832694","reported_name":"Papapetropoulos Spyros","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right-to-Buy)","published_at":"2025-04-18T12:04:03.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":270000,"price":5.16,"value":1393200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested."}],"balance_after":282529,"derivative":{"exercise_price":5.16,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001213900-25-033144","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025033144/ownership.xml","form_type":"4"}},{"id":1169144,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69065,"kind":"person","name":"Davies Peter Miles Winston","position":1,"cik":"0002030200","reported_name":"Davies Peter Miles Winston","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-18T08:03:03.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":6783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."}],"balance_after":6783,"derivative":{"underlying":"Common Stock","underlying_shares":6783},"source":{"system":"sec-edgar","filing":"0001213900-25-033143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030200/000121390025033143/ownership.xml","form_type":"4"}},{"id":1169141,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69063,"kind":"person","name":"Ryan Jane","position":1,"cik":"0002028936","reported_name":"Ryan Jane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-18T08:02:08.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":6783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."}],"balance_after":7013,"derivative":{"underlying":"Common Stock","underlying_shares":6783},"source":{"system":"sec-edgar","filing":"0001213900-25-033142","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028936/000121390025033142/ownership.xml","form_type":"4"}},{"id":1169142,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69064,"kind":"person","name":"Wilson David Ian","position":1,"cik":"0002028949","reported_name":"Wilson David Ian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-18T08:01:05.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":6783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."}],"balance_after":6875,"derivative":{"underlying":"Common Stock","underlying_shares":6783},"source":{"system":"sec-edgar","filing":"0001213900-25-033140","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028949/000121390025033140/ownership.xml","form_type":"4"}},{"id":1169143,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69066,"kind":"person","name":"Fisher Alan","position":1,"cik":"0002028654","reported_name":"Fisher Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-18T08:00:33.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":13566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."}],"balance_after":13658,"derivative":{"underlying":"Common Stock","underlying_shares":13566},"source":{"system":"sec-edgar","filing":"0001213900-25-033139","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2028654/000121390025033139/ownership.xml","form_type":"4"}}]}